Development of biomarker in neurodegenerative disease and psychiatric disorders

Development of biomarker in neurodegenerative disease and psychiatric disorders - Development of biomarker in neuropsychiatric disorders

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000010883

Enrollment

Registered

2013-07-01

Start date

2013-07-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Neurodegenerative disease Psychiatric disorder

Interventions

blood test cognitive test

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: neurodegenerative disease patients psychiatric disorder patients

Exclusion criteria

Exclusion criteria: Body complications in critically ill patients Patients who do not have a person that you can substitute the decision of the principal consent capacity, nor the person

Design outcomes

Primary

Measure	Time frame
Sensitivity,Specificity,positive and negative likelihood ratios of CRMP family protein molecule in the blood for identifying neuropsychiatric disorders.	—

Countries

Japan

Contacts

Public ContactMunetaka Nomoto

Yokohama City University Medical Center Department of Psychiatry

munetaka@yokohama-cu.ac.jp045-261-5656

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026